Suppr超能文献

人多能干细胞诱导血小板面临的机遇与挑战

The Opportunities and Challenges regarding Induced Platelets from Human Pluripotent Stem Cells.

作者信息

Xu Meng-Xue, Liu Li-Ping, Li Yu-Mei, Zheng Yun-Wen

机构信息

Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, Jiangsu Province, China.

School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, Guangdong Province, China.

出版信息

Stem Cells Int. 2021 May 1;2021:5588165. doi: 10.1155/2021/5588165. eCollection 2021.

Abstract

As a standard clinical treatment, platelet transfusion has been employed to prevent hemorrhage in patients with thrombocytopenia or platelet dysfunctions. Platelets also show therapeutic potential for aiding liver regeneration and bone healing and regeneration and for treating dermatological conditions. However, the supply of platelets rarely meets the rising clinical demand. Other issues, including short shelf life, strict storage temperature, and allogeneic immunity caused by frequent platelet transfusions, have become serious challenges that require the development of high-yielding alternative sources of platelets. Human pluripotent stem cells (hPSCs) are an unlimited substitution source for regenerative medicine, and patient-derived iPSCs can provide novel research models to explore the pathogenesis of some diseases. Many studies have focused on establishing and modifying protocols for generating functional induced platelets (iPlatelets) from hPSCs. To reach high efficiency production and eliminate the exogenous antigens, media supplements and matrix have been optimized. In addition, the introduction of some critical transgenes, such as , , and , can also significantly increase hPSC-derived platelet production; however, this may pose some safety concerns. Furthermore, many novel culture systems have been developed to scale up the production of iPlatelets, including 2D flow systems, 3D rotary systems, and vertical reciprocal motion liquid culture bioreactors. The development of new gene-editing techniques, such as CRISPR/Cas9, can be used to solve allogeneic immunity of platelet transfusions by knocking out the expression of . Additionally, the functions of iPlatelets were also evaluated from multiple aspects, including but not limited to morphology, structure, cytoskeletal organization, granule content, DNA content, and gene expression. Although the production and functions of iPlatelets are close to meeting clinical application requirements in both quantity and quality, there is still a long way to go for their large-scale production and clinical application. Here, we summarize the diverse methods of platelet production and update the progresses of iPlatelets. Furthermore, we highlight recent advances in our understanding of key transcription factors or molecules that determine the platelet differentiation direction.

摘要

作为一种标准的临床治疗方法,血小板输注已被用于预防血小板减少症或血小板功能障碍患者的出血。血小板在辅助肝脏再生、骨骼愈合与再生以及治疗皮肤病方面也显示出治疗潜力。然而,血小板的供应很少能满足不断增长的临床需求。其他问题,包括保质期短、严格的储存温度以及频繁血小板输注引起的同种异体免疫,已成为严峻挑战,需要开发高产的血小板替代来源。人类多能干细胞(hPSCs)是再生医学的无限替代来源,患者来源的诱导多能干细胞(iPSCs)可以提供新的研究模型来探索某些疾病的发病机制。许多研究都集中在建立和修改从hPSCs生成功能性诱导血小板(iPlatelets)的方案上。为了实现高效生产并消除外源性抗原,已对培养基补充剂和基质进行了优化。此外,引入一些关键的转基因,如 、 和 ,也可以显著提高hPSC来源的血小板产量;然而,这可能会带来一些安全问题。此外,已经开发了许多新型培养系统来扩大iPlatelets的生产规模,包括二维流动系统、三维旋转系统和垂直往复运动液体培养生物反应器。新的基因编辑技术,如CRISPR/Cas9的发展,可以通过敲除 的表达来解决血小板输注的同种异体免疫问题。此外,还从多个方面对iPlatelets的功能进行了评估,包括但不限于形态、结构、细胞骨架组织、颗粒含量、DNA含量和基因表达。尽管iPlatelets的生产和功能在数量和质量上都接近满足临床应用要求,但它们的大规模生产和临床应用仍有很长的路要走。在这里,我们总结了血小板生产的多种方法并更新了iPlatelets的进展。此外,我们强调了在理解决定血小板分化方向的关键转录因子或分子方面的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b692/8112939/68ec840d657c/SCI2021-5588165.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验